Cel This STREP, coordinated and lead by an SME, will focus on the development of new malaria vaccine candidates with the aim of taking at least one product to the stage of pilot scale up at GLP standard. Products showing most promise, once expressed in the Tetrahymena system, will proceed to antigen testing in vitro and in vivo, to assess their structure and antigenic integrity. We expect to be able to produce at least one product for lead optimisation, safety and toxicology testing according to GLP standards. Combining the expertise of the two university malaria research laboratories with the novel Ciliate-based expression system in development by the SME, will generate several recombinant Tetrahymena thermophila expressing malaria antigens based primarily upon MSP-1 and the var2CSA genes of Plasmodium falciparum. To utilise the capabilities of the participants to the greatest efficiency, (both from the SME and two leading European universities), this STREP will consist of five workpackages: WP1: Project Management WP2: Development of transgenic Tetrahymena expressing MSP-1 Block 2 antigens WP3: Development of transgenic Tetrahymena expressing var2 CSA antigens WP4: GLP pilot scale production and purification of antigens expressed in Tetrahymena WP5: Testing and validation of candidate vaccines This STREP application, coordinated by Cilian AG, will provide an expression platform that is easily able to combine antigens, to develop combinatorial vaccines that may be more promising than the vaccines currently in development. Ciliate-based expression of Plasmodium falciparum proteins in secreted, membrane bound or cytosolic forms will complement the work being done as part of other larger European malaria vaccine development projects. Dziedzina nauki medical and health scienceshealth sciencesinfectious diseasesmalarianatural sciencesbiological sciencesbiochemistrybiomoleculesproteinsmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccinesmedical and health sciencesbasic medicinetoxicology Program(-y) FP6-LIFESCIHEALTH - Life sciences, genomics and biotechnology for health: Thematic Priority 1 under the Focusing and Integrating Community Research programme 2002-2006. Temat(-y) LSH-2005-2.3.0-10 - SME-driven innovations for poverty-related diseases Zaproszenie do składania wniosków FP6-2005-LIFESCIHEALTH-7 Zobacz inne projekty w ramach tego zaproszenia System finansowania STREP - Specific Targeted Research Project Koordynator CILIAN AG Wkład UE Brak danych Adres Johann-Krane-Weg 42 MUENSTER Niemcy Zobacz na mapie Linki Strona internetowa Opens in new window Koszt całkowity Brak danych Uczestnicy (3) Sortuj alfabetycznie Sortuj według wkładu UE Rozwiń wszystko Zwiń wszystko THE UNIVERSITY OF EDINBURGH Zjednoczone Królestwo Wkład UE Brak danych Adres Old College, South Bridge EDINBURGH Zobacz na mapie Linki Strona internetowa Opens in new window Koszt całkowity Brak danych UNIVERSITY OF COPENHAGEN Dania Wkład UE Brak danych Adres Nørregade 10 COPENHAGEN Zobacz na mapie Linki Strona internetowa Opens in new window Koszt całkowity Brak danych BERATUNGSKONTOR KNUST GMBH Niemcy Wkład UE Brak danych Adres Weenermoorerstrasse WEENERMOOR Zobacz na mapie Koszt całkowity Brak danych
